For Novartis, oncology is a key strategic area, but it is still short of dominating the field. It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss ...
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...
Hosted on MSN14h
The ad that got your attention: why early detection is crutial to breast cancer survivalIt’s the Super Bowl ad that had everybody talking. Novartis’s “Your Attention, Please” campaign depicted a variety of women’s ...
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...
Pfizer Inc. has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr.
US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback